Alejandro Duque

Alejandro Duque

Auto-generated profile, based on publicly available information

Alejandro Duque

Grupo de Errores Innatos de la Inmunidad Facultad de Medicina, Universidad de Antioquia, UDEA Medellín Antioquia Colombia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SRSwetha Raman
Swetha Raman
MBMelissa Beilschmidt
Melissa Beilschmidt
MTMinh To
Minh To
KLKevin Lin
Kevin Lin
FLFrancine Lui
Francine Lui
JJJean-Philippe Julien
Jean-Philippe Julien
Aberrant activation of Wnt/β-catenin signaling occurs frequently in cancer. However, therapeutic targeting of this pathway is complicated by the role of Wnt in stem cell maintenance and tissue homeostasis. Here, we evaluated antibodies blocking 6 of the 10 human Wnt/Frizzled (FZD) receptors as potential therapeutics. Crystal structures revealed a common binding site for these monoclonal antibodies (mAbs) on FZD, blocking the interaction with the Wnt palmitoleic acid moiety. However, these mAbs displayed gastrointestinal toxicity or poor plasma exposure in vivo. Structure-guided engineering was used to refine the binding of each mAb for FZD receptors, resulting in antibody variants with improved in vivo tolerability and developability. Importantly, the lead variant mAb significantly inhibited tumor growth in the HPAF-II pancreatic tumor xenograft model. Taken together, our data demonstrate that anti-FZD cancer therapeutic antibodies with broad specificity can be fine-tuned to navigate in vivo exposure and tolerability while driving therapeutic efficacy.

29 January 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ANAllison M. L. Nixon
Allison M. L. Nixon
ADAlejandro Duque
Alejandro Duque
NYNicholas Yelle
Nicholas Yelle
MMMegan McLaughlin
Megan McLaughlin
SDSadegh Davoudi
Sadegh Davoudi
JMJason Moffat
Jason Moffat
Cell surface antigen discovery is of great interest for biomedical research both for isolation of rare cell populations and therapeutic targeting. We developed a rapid, cost-effective, fully in vitro technology which facilities the simultaneous target discovery and human antibody generation on the surface of virtually any cell population of interest. We apply our technique to human colorectal cancer-initiating cells (CICs) and identify hundreds of unique human antibodies. We characterized the top three antibody candidates targeting these CICs and identify their protein targets as integrin α7 (ITGA7), HLA-A1 and integrin β6 (ITGB6). We demonstrate that these antibodies can be used to isolate self-renewing colorectal CICs, and that the integrin α7 antibody can prospectively identify glioblastoma brain tumor initiating cells as well as human muscle stem cells. We also demonstrate that genetic ablation of integrin β6 impedes colorectal CIC function. The methodology can be readily applied to other cell populations including stem cells, cancer, or immune cells to facilitate the rapid identification of novel targets and simultaneous generation of potent and specific antibodies with therapeutic potential.

22 June 2025 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
JÁJesús A. Álvarez‐Álvarez
Jesús A. Álvarez‐Álvarez
EVEstefanía Vásquez‐Echeverri
Estefanía Vásquez‐Echeverri
ISIsaura P. Sánchez
Isaura P. Sánchez
SHSebastián Gutierrez Hincapié
Sebastián Gutierrez Hincapié
ADAlejandro Gallon Duque
Alejandro Gallon Duque
CTClaudia M. Trujillo‐Vargas
Claudia M. Trujillo‐Vargas